The Pharmacological Treatment and Management of Obesity
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Obesity is a pandemic with many complications that increase the societal disease burden and cost of health care, and decrease longevity and quality of life. Currently, 1 in 3 adults in the United States is obese. Physicians must therefore regularly confront obesity and its consequent diseases, and develop strategies for effective treatment and management. This article summarizes current lifestyle modifications, pharmacological treatment, and surgical options for the management of obesity and discusses the benefits, limitations, and risks of each. As insights are gained into the pathophysiology of a gut-brain neurochemical feedback axis governing satiety and feeding behavior, targets for new pharmacotherapies are being developed. In particular, gut hormone analogs are an attractive antiobesity therapy because they appear to lack the adverse effects historically associated with central nervous system-acting agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
DONNELLY, J. E., BLAIR, S. N., JAKICIC, J. M., MANORE, M. M., RANKIN, J. W., & SMITH, B. K. (2009) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181949333 · Cited by 2,658
Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis
Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Jensen, M. D., Pories, W. J., Bantle, J. P., & Sledge, I. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.041 · Cited by 2,551 · cited 1×
“1% of patients.(51) Diabetes remission and weight loss rates were highest for malabsorptive procedures and lowest for restrictive procedures.”
BackgroundCaloric Restriction Delays Disease Onset and Mortality in Rhesus Monkeys
Colman, R. J., Anderson, R. M., Johnson, S. C., Kastman, E. K., Kosmatka, K. J., Beasley, T. M., Allison, D. B., Cruzen, C., Simmons, H. A., Kemnitz, J. W., et al. (2009) · Science · doi:10.1126/science.1173635 · Cited by 2,277
Gastrointestinal Surgery for Severe Obesity
Panel, C. D. C. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-12-956 · Cited by 2,163
Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin Deficiency
Farooqi, I. S., Jebb, S. A., Langmack, G., Lawrence, E., Cheetham, C. H., Prentice, A. M., Hughes, I. A., McCamish, M. A., & O'Rahilly, S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411204 · Cited by 1,998 · cited 1×
“Congenital leptin deficiency in humans is a rare form of severe early onset obesity, which is reversible with leptin therapy.(65) However, except in the rare instances of total leptin deficiency, serum leptin is elevated in obesity, and obese individuals have CNS resistance to leptin-mediated satiety.”
BackgroundComparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates
Sacks, F. M., Bray, G. A., Carey, V. J., Smith, S. R., Ryan, D. H., Anton, S. D., McManus, K., Champagne, C. M., Bishop, L. M., Laranjo, N., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0804748 · Cited by 1,966
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Dansinger, M. L., Gleason, J. A., Griffith, J. L., Selker, H. P., & Schaefer, E. J. (2005) · JAMA · doi:10.1001/jama.293.1.43 · Cited by 1,726
Adherence to Mediterranean diet and health status: meta-analysis
Sofi, F., Cesari, F., Abbate, R., Gensini, G. F., & Casini, A. (2008) · BMJ · doi:10.1136/bmj.a1344 · Cited by 1,717 · cited 1×
“Substantial protection against type 2 diabetes, cardiovascular mortality, cancer mortality, and development of Parkinson’s disease and alzheimer’s disease.(78) reduction in overall mortality and improvement in general health status.”
BackgroundValvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632 · cited 2×
“However, a high rate of cardiac valvular abnormalities was noted in patients taking this combination, which led to the withdrawal of fenfluramine from the market.(35) Phentermine monotherapy has not been linked to disproportionate incidence of cardiac valvular disease.”
BackgroundSitting time and mortality from all causes, cardiovascular disease, and cancer
KATZMARZYK, P. T., CHURCH, T. S., CRAIG, C. L., & BOUCHARD, C. (2009) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181930355 · Cited by 1,611
Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604 · cited 1×
“Initial studies have utilized an injectable form of PYY 3–36 , which has produced a reduction of food intake in humans.(63) The most commonly known adverse effect is dose-related nausea.”
MethodSelf-citationBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Ross, R., Dagnone, D., Jones, P. J. H., Smith, H., Paddags, A., Hudson, R., & Janssen, I. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-2-200007180-00008 · Cited by 1,435
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Gardner, C. D., Kiazand, A., Alhassan, S., Kim, S., Stafford, R. S., Balise, R. R., Kraemer, H. C., & King, A. C. (2007) · JAMA · doi:10.1001/jama.297.9.969 · Cited by 1,051
Nordmann, A. J., Nordmann, A., Briel, M., Keller, U., Yancy, W. S., Brehm, B. J., & Bucher, H. C. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.3.285 · Cited by 973 · cited 1×
“Similar efficacy to low-fat diets for long-term weight loss.(76) beneficial effects on metabolic risk factors, such as insulin sensitivity and blood pressure, independent of weight loss.”
BackgroundDavidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947 · cited 1×
“Orlistat lowers hemoglobin A 1c and serum lipids beyond what can be explained by weight loss alone.(31,32) There are no major safety concerns with orlistat, but the drug does cause a number of gastrointestinal side effects.”
BackgroundMulticenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911 · cited 1×
“2 kg) and maintenance of weight loss at 2 years (68% vs 50%) with lorcaserin as compared with placebo.(58) There were no significant concerns regarding adverse events or valvulopathy, although more long-term follow-up of treated subjects will be needed to allay these concerns.”
BackgroundLong term pharmacotherapy for obesity and overweight: updated meta-analysis
Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. W. (2007) · BMJ · doi:10.1136/bmj.39385.413113.25 · Cited by 801
Meta-Analysis: Pharmacologic Treatment of Obesity
Li, Z., Maglione, M., Tu, W., Mojica, W., Arterburn, D., Shugarman, L. R., Hilton, L., Suttorp, M., Solomon, V., Shekelle, P. G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-7-200504050-00012 · Cited by 774
Svetkey, L. P. (2008) · JAMA · doi:10.1001/jama.299.10.1139 · Cited by 748
Miller, W., Koceja, D., & Hamilton, E. (1997) · International Journal of Obesity · doi:10.1038/sj.ijo.0800499 · Cited by 686 · cited 1×
“Likewise, exercise therapy in combination with dietary therapy has not been shown to be superior to dietary therapy alone.(18) The main established benefit of exercise in the management of obesity is the maintenance of weight loss after weight reduction.”
BackgroundHollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Pancreatic Polypeptide Reduces Appetite and Food Intake in Humans
Batterham, R. L., Le Roux, C. W., Cohen, M. A., Park, A. J., Ellis, S. M., Patterson, M., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030630 · Cited by 496
Self-citationRoth, J. D., Roland, B. L., Cole, R. L., Trevaskis, J. L., Weyer, C., Koda, J. E., Anderson, C. M., Parkes, D. G., & Baron, A. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706473105 · Cited by 436
Freedman, M. R., King, J., & Kennedy, E. (2001) · Obesity Research · doi:10.1038/oby.2001.113 · Cited by 421 · cited 1×
“800 kcal/day but below daily energy expenditure requirements and unconventional diets, such as very-low-calorie (, 800 kcal/day) and fad diets.(10) The more widely prescribed diets are summarized in Table 1.”
BackgroundLifestyle modification for the management of obesity
Wadden, T. A., Butryn, M. L., & Wilson, C. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.051 · Cited by 406 · cited 2×
“Following treatment, patients typically regain 30% to 35% of their lost weight in 1 year.(8) Thus, all too frequently, the cornerstone of obesity management is missing.”
BackgroundThe Evolution of Very‐Low‐Calorie Diets: An Update and Meta‐analysis
Tsai, A. G., & Wadden, T. A. (2006) · Obesity · doi:10.1038/oby.2006.146 · Cited by 371
Effect of Exercise on 24-Month Weight Loss Maintenance in Overweight Women
Jakicic, J. M. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.14.1550 · Cited by 370 · cited 1×
“The main established benefit of exercise in the management of obesity is the maintenance of weight loss after weight reduction.(20) The American College of Sports Medicine (ACSM) has drafted a consensus statement on the types of exercise programs recommended for the treatment of obesity.”
BackgroundWynne, K., Park, A. J., Small, C. J., Meeran, K., Ghatei, M. A., Frost, G. S., & Bloom, S. R. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803344 · Cited by 363 · cited 1×
“Oxyntomodulin inhibits food intake and increases energy expenditure in humans.(67) TKS1225 is a long-acting synthetic analog of oxyntomodulin and is in phase 1 trials.”
BackgroundSelf-citationBupropion SR Enhances Weight Loss: A 48‐Week Double‐Blind, Placebo‐ Controlled Trial
Anderson, J. W., Greenway, F. L., Fujioka, K., Gadde, K. M., McKenney, J., & O'Neil, P. M. (2002) · Obesity Research · doi:10.1038/oby.2002.86 · Cited by 315 · cited 1×
“1% of initial body weight compared with 5% with placebo during a 24-week trial, with increased maintenance of lost weight at 48 weeks.(48) Larger and longer-duration trials are needed before bupropion can be recommended as a primary obesity medication.”
BackgroundHollander, P. A., Levy, P., Fineman, M. S., Maggs, D. G., Shen, L. Z., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.784 · Cited by 307 · cited 5×
“Exenatide long-acting release is a sustained-release formulation of exenatide, which is administered once weekly, and is currently being studied in clinical trials, showing encouraging preliminary results.42 Pramlintide Pramlintide is a synthetic analog of amylin (ie, islet amyloid polypeptide) that has recently been…”
BackgroundInfluentialWhitehouse, F., Kruger, D. F., Fineman, M., Shen, L., Ruggles, J. A., Maggs, D. G., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Care · doi:10.2337/diacare.25.4.724 · Cited by 264 · cited 5×
“Exenatide long-acting release is a sustained-release formulation of exenatide, which is administered once weekly, and is currently being studied in clinical trials, showing encouraging preliminary results.42 Pramlintide Pramlintide is a synthetic analog of amylin (ie, islet amyloid polypeptide) that has recently been…”
BackgroundInfluentialAlhassan, S., Kim, S., Bersamin, A., King, A. C., & Gardner, C. D. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.8 · Cited by 220 · cited 2×
“These trials highlight that dietary adherence and caloric restriction appear to be more important than macronutrient composition in determining weight loss, and any diet that is adhered to will produce a modest weight loss.(13) Adherence is poor for most diets.”
BackgroundRatner, R. E., Maggs, D., Nielsen, L. L., Stonehouse, A. H., Poon, T., Zhang, B., Bicsak, T. A., Brodows, R. G., & Kim, D. D. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00589.x · Cited by 217 · cited 1×
“5-kg weight loss at 2 years.(38,39) Weight loss with liraglutide at 1 year was 2 to 2.”
BackgroundComparison of continuous and intermittent anorectic therapy in obesity.
Munro, J. F., MacCuish, A. C., Wilson, E. M., & Duncan, L. J. (1968) · BMJ · doi:10.1136/bmj.1.5588.352 · Cited by 215 · cited 1×
“8 kg, respectively).(34) Fenfluramine was used in combination with phentermine (“fen-phen”) in the 1990s, and this combination was effective in weight”
MethodAstrup, A., Madsbad, S., Breum, L., Jensen, T. J., Kroustrup, J. P., & Larsen, T. M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61525-1 · Cited by 193
The fundamental drivers of the obesity epidemic
James, W. P. T. (2008) · Obesity Reviews · doi:10.1111/j.1467-789x.2007.00432.x · Cited by 179 · cited 1×
“Lifestyle Interventions Excessive calorie intake and a sedentary lifestyle promote weight gain, which leads to obesity.(7) Lifestyle interventions such as food intake restriction, exercise, and behavior modification form the cornerstone of obesity management.”
BackgroundDrug Treatment of the Overweight Patient
Bray, G. A., & Ryan, D. H. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.053 · Cited by 115
Cited by
Garvey, W. T., Ryan, D. H., Look, M., Gadde, K. M., Allison, D. B., Peterson, C. A., Schwiers, M., Day, W. W., & Bowden, C. H. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.024927 · Cited by 716
Economic costs of overweight and obesity
Lehnert, T., Sonntag, D., Konnopka, A., Riedel-Heller, S., & König, H.-H. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.01.002 · Cited by 299
Garvey, W. T., Ryan, D. H., Henry, R., Bohannon, N. J. V., Toplak, H., Schwiers, M., Troupin, B., & Day, W. W. (2014) · Diabetes Care · doi:10.2337/dc13-1518 · Cited by 215
Potential use of exenatide for the treatment of obesity
Folli, F., & Guardado Mendoza, R. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.630660 · Cited by 26
“With these drugs, patients can achieve a 2 -- 5% of weight loss, and they may have side effects, which highlight the need of new therapeutic options for obesity and the establishment of clear clinical criteria specifying the contraindications and the characteristics of the patients that can make them more susceptible…”
BackgroundThe risk of cardiovascular complications with current obesity drugs
Chao, A. M., Wadden, T. A., Berkowitz, R. I., Quigley, K., & Silvestry, F. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1806234 · Cited by 23
Metadata
- Authors
- Hussain, S. S., & Bloom, S. R.
- Venue
- Postgraduate Medicine
- Publisher
- Informa UK Limited
- Published
- 2011-01
- Volume
- 123
- Issue
- 1
- Pages
- 34-44
- ISSN
- 0032-5481 (ISSN-L)
- 1941-9260
- OpenAlex
- W1972224209
- Cited by
- 54
- References
- 42
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.